Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
HIV/AIDSHIV Prevention
Interventions
DRUG

Tenofovir Douche

660 mg TFV in 125 mL hypo-osmolar solution

Trial Locations (3)

21287

Johns Hopkins University, Baltimore

27599

University of North Carolina - Chapel Hill, Chapel Hill

30322

Emory University, Atlanta

All Listed Sponsors
collaborator

University of North Carolina, Chapel Hill

OTHER

collaborator

Emory University

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of Pennsylvania

OTHER

NCT04686279 - Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM) | Biotech Hunter | Biotech Hunter